Tuesday, June 6, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Defense + Military

US Army Special Immunizations Program for Rift Valley Fever Vaccine

by Global Biodefense Staff
May 25, 2017
Biodefense Request for Information (RFI)

The U.S. Army Medical Research and Materiel Command (USAMRMC) Special Immunizations Program (SIP) currently offers Investigational New Drug (IND) products to both military and civilian personnel at risk for pathogen and toxin exposure.

The current portfolio of SIP vaccines consists of legacy products produced primarily by the Salk Institute in the 1960’s to the 1980’s that are not on a path for FDA licensure. There is a current need to have one of these vaccines, originally vialed in multi-dose format, re-vialed into single-dose vials.

MP-12 is a live-attenuated vaccine developed to produce a protective immune response against Rift Valley Fever Virus (RVF), a virus endemic to sub-Saharan Africa. The vaccine is a lyophilized, IND product produced by The Salk Institute Government Services Division (TSI-GSD) in the nineteen eighties.

The SIP is looking for a facility with sterile fill-finish and lyophilization capability to re-vial between 250 and 1000 20 mL vials to single-dose vials (5000-20000 vials). The number of vaccine vials processed will be specified at a later time and will depend on capacity of the facility, cost, and needs of the product sponsor.

The facility should indicate the capability to perform, support, or otherwise arrange for lot-release and stability testing that could include sterility, endotoxin, mycoplasma, potency (virus titer measurement by plaque assay), and other assays as agreed upon.

Further details are available via Solicitation Number: W81XWH-RFI-SIP2. The response deadline is Jun 05, 2017 4:00 pm Eastern.

Tags: RFIRift Valley FeverVaccines

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics
Industry News

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023
Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC